Head-To-Head Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Werewolf Therapeutics (NASDAQ:HOWL)

Kymera Therapeutics (NASDAQ:KYMR) and Werewolf Therapeutics (NASDAQ:HOWL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.

Valuation & Earnings

This table compares Kymera Therapeutics and Werewolf Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21 million	209.52	-$311.35 million	($3.57)	-27.97
Werewolf Therapeutics	$1.88 million	9.68	-$60.82 million	($1.24)	-0.30

Werewolf Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kymera Therapeutics and Werewolf Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Werewolf Therapeutics	N/A	-208.23%	-75.12%

Risk and Volatility

Kymera Therapeutics has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500.

Institutional & Insider Ownership

64.8% of Werewolf Therapeutics shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Kymera Therapeutics and Werewolf Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1	0	21	1	2.96
Werewolf Therapeutics	1	4	2	0	2.14

Kymera Therapeutics currently has a consensus target price of $117.14, indicating a potential upside of 17.29%. Werewolf Therapeutics has a consensus target price of $3.75, indicating a potential upside of 901.07%. Given Werewolf Therapeutics’ higher possible upside, analysts clearly believe Werewolf Therapeutics is more favorable than Kymera Therapeutics.

Summary

Kymera Therapeutics beats Werewolf Therapeutics on 8 of the 15 factors compared between the two stocks.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.